It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks. 580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.03. As such I have modelled similar, although I have included an additional revenue stream from new products which I expect to be minor in nature but ultimately contributing an additional $1.5bn to the top line. Read our dividend analysis for ABBV. Skyrizi has also been approved to treat Crohn's Disease, an added bonus and another multi-billion dollar market. Venclexta continues to pick up momentum with sales up 16% to >$500m in Q2'22, and I forecast the drug to exceed $3.2bn in revenues by the end of the decade. AbbVie Fair Value Forecast for 2023 - 2025 - 2030 In the last two years, AbbVie's Price has grown, increasing from $91.55 to $130.05 - an increase of 42.06%. Abbvie (ABBV) stock price prediction is 262.23586323343 USD. The Abbvie Both Leqembi and Donanemab are potential $5bn - $10bn selling assets, but both drugs still have safety questions to answer and not certain to be made eligible for reimbursement. Aesthetics was propped up by growing sales of Botox - up 12% year-on-year to $678m, but let down by sales of Juvederm, which management put down to lockdown regulations in China, and the "suspension" of operations in Russia. My calculation is that Humira revenues in 2023 will be 80% of the 2022 figure, or $16.7bn. Management believes these 2 drugs could one day generate $15bn in peak sales, going a long way to solving the Humira loss of exclusivity ("LOE") problem. Forecast target price for 03-06-2023: $ 152.58. AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com GB The important point here is that physicians will not necessarily be under any pressure to switch patients from Humira to a biosimilar, given, as Gonzalez puts it: there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. It's hard to argue against Skyrizi and Rinvoq's performance to date, however, and with the total addressable market across all immunology indications likely well in excess of $100bn, I feel fairly comfortable that AbbVie can grow this division's revenues even as the world's biggest ever selling drug exits stage left. Is this happening to you frequently? Management has previously stated that it expects total revenues to decline in 2023 following the Humira LOE, followed by a return to growth in 2024, and a "high single digit CAGR" maintained through the remainder of the decade. If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. 326 E 8th St #105, Sioux Falls, SD 57103 In the U.S. dermatology segment, where approximately 30% of patients exhibit both skin and joint involvement, Skyrizi is already achieving an in-play patient share of nearly 20%. This represents a $5.92 dividend on an annualized basis and a dividend yield of 3.79%. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. 8.05% For ABBVIE INC stock forecast for 2023, 10 predictions are offered for each month of 2023 with average ABBVIE INC stock forecast of $156.58, a high forecast of $160.07, and a low forecast of $152.24. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049. approvals of Humira, Skyrizi, Rinvoq (AbbVie JPM Healthcare conference presentation). To be sure, AbbVie is modeling for a tough year in 2023 for the aesthetics market. This suggests a possible upside of 3.2% from the stock's current price. We expect proof-of-concept data from roughly a dozen additional early stage oncology opportunities over the next couple of years. AbbVie (ABBV) stock Forecast for 2021 - 2025 - PandaForecast.com ABBV currently yields 4.1% and has raised its dividend every year since 2013. Since then, ABBV stock has decreased by 3.4% and is now trading at $156.06. The analysts 12-month consensus ABBV stock price target was $159.75. Is this happening to you frequently? My EPS figure increases slightly between 2022 and 2023, whilst AbbVie has suggested it will be down slightly before beginning to accelerate towards the end of the decade, as revenues correspondingly begin to climb sharply once the worst of the Humira LOE is over. AbbVie is a leader in ESG and sustainability. ABBV closed at $152.49 on 29 June, which was above its 200-day moving average (MA) of 136.42, indicating a bullish signal for the stocks price movement ahead, according to data from TradingView. Since then, however, the stock price has fallen 18% to. AbbVie Inc. (ABBV) Stock Forecast & Price Prediction For 2023 2024 2025 An investment in AbbVie is not without risk, but my contention is that this Pharma is in good hands - CEO Gonzalez has made few mistakes during his near-decade in charge - and will emerge from the Humira LOE a stronger and more diverse company. Our daily ratings and market update email newsletter. Kateryna Onyshchuk/iStock via Getty Images. I'm on twitter @edmundingham. The Abbvie stock forecast for 2025 had the price at $259.018. Allergan was a troubled company in many ways, but there is no doubting the strength of its products and pipeline. Multidrug Resistant Bacteria Treatment Market - MarketWatch I am not receiving compensation for it (other than from Seeking Alpha). What guidance has AbbVie issued on next quarter's earnings? In other words, management believes the LOE of Humira - despite it being the world's best-selling drug - will not hinder growth at the company. Botox accounts for the bulk of the companys Aesthetics portfolio revenue and about 4% of the net as of 2022. AbbVie could be the biggest global Pharma by revenue generation in 2028. View which stocks are hot on social media with MarketBeat's trending stocks report. For the next nine years, the forecast is for Revenue to grow by 3.57%. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. Based on an average daily volume of 5,600,000 shares, the days-to-cover ratio is currently 2.1 days. Read the conference call transcript. (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. Without the additional patents - >130 in total - Humira would have lost its market exclusivity in 2016, but having eventually lost protection in Europe, which has resulted in a sales decline from $6.3bn in 2018, to ~$2.7bn in 2022, Humira will finally face generic competition in the US from the beginning of this year. It should be noted that the strength of the competition AbbVie faces from other Pharma's desperate to claim a larger share of the immunology markets after Humira's LOE is fierce - Eli Lilly's (LLY) Olumiant, Pfizer's (PFE) Zeljanz, Amgen's Otezla, Bristol Myers Squibb's (BMY) Zeposia, Johnson & Johnson's (JNJ) Tremfya, Novartis' (NVS) Cosentyx and Regeneron (REGN) / Sanofi's (SNY) Dupixent to name a few. Forecast . Factset: FactSet Research Systems Inc.2019. The company projects the U.S. toxin market (where Botox is the top product) will decline by mid-single digits. In my opinion, based on the current portfolio, AbbVie shares look undervalued below $160, but the upside above that price is limited, unless management is able to commercialize more products between now and the end of the decade, in order to achieve what looks like a very ambitious goal in driving high-single-digit revenue growth in the second half of this decade. To summarize, although AbbVie does not have the same clout in oncology as it does in immunology - as evidenced perhaps by the declining sales of Imbruvica - it is clearly an area of focus for management. On average, analysts rate AbbVie stock as a buy. Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. Analysts have tipped the drug to achieve peak sales of $2.75bn, and although the emergence of CAR-T therapies and some concerns around safety - notably cases of cytokine release syndrome ("CRS') - persist, this revenue figure is achievable in my view. The company employs 50,000 workers across the globe. The company also successfully completed the acquisition of Syndesi Therapeutics SA in March. When I began this post it was in my mind to give AbbVie stock a "Hold" rating owing to an underwhelming - on some levels - set of Q2'22 earnings, some concerns around high revenue generating products such as Imbruvica, Juvederm, and Restasis, the disappearance of the Women's Health division, the imminent LOE for Humira and the high levels of debt. I had felt this could be an issue for Skyrizi and Rinvoq, given it is rare for a drug to be as dominant as Humira was, but although the level of competition is fierce, both drugs are more than meeting expectations, and with the entire auto-immune market worth as much as $45 - $50bn, it does seem possible that Skyrizi and Rinvoq could one day generate >$20bn revenues between them, as management hopes. Real-time analyst ratings, insider transactions, earnings data, and more. Excluding items, AbbVie earned $3.31 per share, beating estimates of $3.29 . This included an unfavourable impact of $0.08 a share related to acquired in-process research and development (IPR&D) and milestones expenses incurred during the March quarter. AbbVie's Q2'22 earnings threw up some positives and negatives for investors to contemplate. Please disable your ad-blocker and refresh. Retail sales were up but so was inflation which meant more volatility for stocks. If you rely on the information on this page then you do so entirely on your own risk. AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 3.83%. It . Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. The "King Of Quants" sees 10X potential Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. The major market events for the week ahead right in your inbox. This indicates that the company will be able to sustain or increase its dividend. Only you can design whether Abbvie stock is the right investment for you. If you have an ad-blocker enabled you may be blocked from proceeding. The company has a robust pipeline of new products that are in some stage of clinical trials. Let's begin our analysis with the immunology division. In other words, no Humira, no problem! ET comments How often does AbbVie pay dividends? It now expects full-year profit in the range of $13.92-$14.12 a share. This figure could eventually end up substantially larger - according to Gonzalez: We've begun to see some very exciting data from several solid tumor programs, including our anti-GARP antibody ABBV-151, and our PTK7 ADC, ABBV-647. The five-year dividend growth rate is just below 18%. The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska druba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacuticos S.A. de C.V., AbbVie Farmacutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S. r.l., AbbVie Investments Limited, AbbVie Investments S. r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementr GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S. r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. AbbVie Stock: Still A Solid Buy After Modeling Sales To 2030 Based on earnings estimates, AbbVie will have a dividend payout ratio of 54.11% next year. The Immunology division looks strong, even factoring in the patent cliff faced by $20 billion-selling Humira. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. Although management reminded analysts that "Imbruvica continues to be the total market share leader across all lines of therapy in CLL", the outlook does not look especially promising. I have downgraded my forecasts to 2016 accordingly however to 2% annual growth. AbbVie has 5 focus areas for its research and products. AbbVie has received a consensus rating of Hold. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. AbbVie projected sales - immunology (my forecasts and assumptions). According to CompaniesMarketCap, the biopharmas market capitalisation stood at $272.38bn, making it the worlds 30th most valuable company. Get daily stock ideas from top-performing Wall Street analysts. The lowest target is $136.35 and the highest is $210. The dividend payout ratio is 89.56%. When looking for ABBV stock forecasts, its important to bear in mind that analysts forecasts can be wrong. Currently, AbbVie sees a significantly higher portion of every dollar end up as cash to do with what they please. The company reported its first revenue for Botox competitor Daxxify. Date. Venclexta - a "first-in-class BCL-2 inhibitor for multiple hematological malignancies", according to Gonzalez, is forecast for strong growth, whilst Gonzalez has name checked 3 new drugs he expects to be approved by 2026. Trial results demonstrated an overall response rate of 63% and a median duration of response of 12 months, where 39% of patients had already tried a CAR-T cell therapy. As with debt, if approval and revenue targets aren't met, it can quickly result in a loss of faith in the company. The weighted average cost of capital I estimate to be 9.6% - I tend to use a WACC of 10% for most Big Pharma analysis. Johnson & Johnson Stock Forecast 2023 - 2025 - 2030 The dividend payout ratio of AbbVie is 89.56%. How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, One Way to Earn More From Dividend Stocks, How to Choose a Winning Dividend Investing Strategy, 3 Industries Leading the Stock Market Rebound, Oil Tankers Boost Dividends, See Continued Robust Business In '23. Payout ratios above 75% are not desirable because they may not be sustainable. I have no business relationship with any company whose stock is mentioned in this article. As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. In 2022, Humira revenues will likely reach $21bn, which will see the drug overtake cholesterol-lowering Lipitor as the best-selling drug of all-time. call (03) 8658 0539 support.au@capital.com. GSK Free Cash Flow Forecast for 2023 - 2025 - 2030. Net earnings also saw a steep rise to $4.49bn from $3.55bn, while net revenue jumped to $13.54bn from 13.01bn. Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. There has been a raft of price-moving news for Abbvie, which may positively affect the stock price. AbbVie passed that onto its 2022 guidance. Note that analysts ABBV stock forecasts can be wrong. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. The first is Epcoritamab, a CD3xCD20 bispecific for B-cell malignancies, including DLBCL and follicular lymphoma, which AbbVie expects will be approved this year. AbbVie will have to drop its price point to compete with the generics however, plus there is the 10% of the market it is not covered for, so an overall 20% decline in revenues in 2023 seems accurate. Out of the most recent ratings, BMO Capital Markets Gary Nachman raised its price target from $161 to $174 with an outperform rating, while Truist Financial analyst Robyn Karnauskas raised the Abbvie stock prediction from $118 to $135 while raising rating to a buy. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares. See AbbVie Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. Eye Care, Other products Division Projected Revenues to 2030 (my table and assumptions ). The company may not generate as much excitement as some of the other members of the "Big 8" - most notably Eli Lilly and its weight loss franchise, but the path to revenue growth, expanding margins and a growing share price is clear. Our Product Disclosure Statement (PDS) and Target Market Determination provides important information about our products and who our products are more likely to be suited to Capital.com does not provide financial or investment advice and you should seek independent advice if you are unsure of the risks or whether our products are suitable for you. Neurology also looks strong although aesthetics, eye care and oncology have something to prove. As of 30 June, analysts price predictions compiled by MarketBeats and long-term forecasts by Wallet Investor projected that the ABBV stock price could rise. Ever since its split from Abbott Laboratories (ABT) in 2012 AbbVie (NYSE:ABBV) has delivered strong returns for investors - its stock price having risen overall from $30, to $149 per share at the time of writing - trading down slightly from its all-time high of >$160 achieved in early December last year. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Our first quarter results highlight the diversity of our portfolio and include compelling performance from key growth drivers Skyrizi, Rinvoq, Aesthetics and Neuroscience. Gene therapies have been a long time coming, having first been popularized in the early noughties. (ABBV) AbbVie Stock Predictions from the Leading Provider of Short and Long Term Stock Price Forecasts. As of 2023 February 22, Wednesday current price of ABBV stock is 151.340$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Abbvie stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. After creating the income statement I prepare the discounted cash flow/EBITDA multiple analysis. All rights reserved. Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year., ABBV has done very well to add to its impressive gains from the past couple of years. AbbVie Stock Forecast 2023 - 2025 - 2030 | StockForecast.com The division delivered >$1.65bn in sales in Q2'22, up >15% year-on-year, and with Vraylar, Ubrelvy and possibly Qulipta all earmarked for blockbuster sales - $4bn in the case of Vraylar - my forecasting suggests this division could double in size by 2030, from ~$6.6bn revenues generated in FY22, to >$13.5bn by 2030. AbbVie (ABBV) Stock Forecast & Price Target - TipRanks The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. Abbvie Inc quote is equal to 152.710 USD at 2023-02-27. By creating a free account, you agree to our, In Britain, warm hubs emerge to beat soaring energy costs, In Chicago, adapting electric buses to winters challenges, Global race to boost electric vehicle range in cold weather, Ukraine ally Kallas fights for reelection in Estonia vote, Paid express lanes grow more popular in once-reluctant South, Pot vote has Oklahoma hungry to rake in green from Texas, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, Chief Financial Officer & Executive Vice President, BREAKING: Tiny biotech successfully treats blindness, Fed's Shocking New Plan to Control Your Money. As well as the stock price gains AbbVie has always paid a handsome dividend - which has increased by 270% since the Pharma's inception, currently paying $1.48 per quarter, for a current yield of 4% - the highest in the large Pharmaceutical sector. The company is a member of the Fortune 100 and one of the Fortune 100s Best Companies To Work For. There is an element of risk to that as clinical trial failures are common, even for a giant like AbbVie, and even CEO Gonzalez may be forced to backtrack on some of his blockbuster sales projections. The most recent increase was . As we can see, sales of Humira are still climbing, with losses in Europe - where revenues fell by 14% to $699m - offset by growth in the US, to $4.7bn, up 10% year-on-year. These are Immunology, Oncology, Neurology, Virology and Eye Care. AbbVie has a P/B Ratio of 15.97. Price target. That reflects uncertainty about what the future holds for AbbVie. I have plugged my revenue expectations into this table knowing that they closely match AbbVie management's own expectations based on what they have said in public. Fawad Razaqzada, market analyst for City Index and FOREX.com, commenting to Capital.com, said: As of 30 June, analyst ratings compiled by MarketBeat shared different price targets for Abbvie stock. ABBV-916 is therefore a real opportunity for AbbVie to develop a more effective and safer drug in the same class and claim a sizeable share of a 6m patient market. The surge in revenues can primarily be attributed to its Allergan. According to the algorithm-based forecaster Wallet Investor in its Abbvie stock forecast for 2022, the price could reach $169.852 by the end of December, $199.491 by 2023 and $229.304 by 2024. All rights reserved. This year is off to a strong start. I have speculatively assigned peak sales of $2bn, although it should be noted that success here is far from guaranteed, although if AbbVie did succeed with ABBV916 sales could be 2 or 3x higher than my forecast. According to 34 stock analysts, the average 12-month stock price forecast for AbbVie stock is $166.14, which predicts an increase of 7.62%. AbbVie probably does not want to be recognized as simply an immunology giant however, it wants to be substantially more diversified and like all major Pharma's it has a strong long-term focus on oncology. I am not receiving compensation for it (other than from Seeking Alpha). This has been in spite of a string of macroeconomic headwinds such as the ongoing Russia-Ukraine war that has contributed to record high inflation in the US and the UK, and the companys psoriatic arthritis drug Adalimumab, known as Humira, facing biosimilar rivals in the US from 2023.